B-Cell Non-Hodgkin Lymphoma Market

Market Overview:

The 7 major B-cell non-Hodgkin lymphoma markets are expected to exhibit a CAGR of 5.83% during 2024-2034.

The B-cell non-Hodgkin lymphoma market has been comprehensively analyzed in IMARC's new report titled "B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B-cell non-Hodgkin lymphoma (NHL) refers to a type of cancer that originates from B cells, a category of white blood cells involved in the immune system's defense against infections. The symptoms of the ailment can vary depending on the specific subtype, stage of the disease, and organs or tissues affected. Some of the common indications are painless swelling of lymph nodes in the armpits, neck, or groin, unexplained weight loss, persistent fatigue, night sweats, fever, itching, etc. Various other possible symptoms may include abdominal pain or swelling, chest pain, difficulty breathing, bone pain, etc. The diagnosis of B-cell non-Hodgkin lymphoma involves a combination of clinical evaluation, imaging tests, and laboratory investigations. A healthcare professional will review the patient's medical history and conduct a physical exam to assess lymph nodes and organs. A biopsy of an affected lymph node or other involved tissues is usually performed to confirm the diagnosis and determine the specific subtype of B-cell NHL. Numerous additional tests, including blood work, immunophenotyping, molecular testing, etc., may be conducted to provide further information about the disease's characteristics.

The increasing cases of translocations, deletions, and mutations in specific genes that can disrupt the normal functioning of the B cells are primarily driving the B-cell non-Hodgkin lymphoma market. In addition to this, the rising prevalence of several associated risk factors, such as certain autoimmune conditions like rheumatoid arthritis and Sjögren's syndrome, exposure to ionizing radiation, viral infections, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, including ibrutinib and idelalisib, which interfere with signaling pathways or cellular processes essential for cancer cell survival, thereby leading to tumor regression, is further bolstering the market growth. Apart from this, the inflating application of chimeric antigen receptor T-cell (CAR-T) therapy, which involves modifying a patient's own T-cells to express a receptor that recognizes and attacks cancer cells expressing particular antigens, like CD19, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel immune checkpoint inhibitors, enabling the immune system to better recognize and attack lymphoma cells, is expected to drive the B-cell non-Hodgkin lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the B-cell non-Hodgkin lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B-cell non-Hodgkin lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B-cell non-Hodgkin lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the B-cell non-Hodgkin lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the B-cell non-Hodgkin lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current B-cell non-Hodgkin lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the B-cell non-Hodgkin lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the B-cell non-Hodgkin lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the B-cell non-Hodgkin lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of B-cell non-Hodgkin lymphoma across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of B-cell non-Hodgkin lymphoma by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of B-cell non-Hodgkin lymphoma by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with B-cell non-Hodgkin lymphoma across the seven major markets?
• What is the size of the B-cell non-Hodgkin lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of B-cell non-Hodgkin lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

B-Cell Non-Hodgkin Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for B-cell non-Hodgkin lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B-cell non-Hodgkin lymphoma market?
• What are the key regulatory events related to the B-cell non-Hodgkin lymphoma market?
• What is the structure of clinical trial landscape by status related to the B-cell non-Hodgkin lymphoma market?
• What is the structure of clinical trial landscape by phase related to the B-cell non-Hodgkin lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the B-cell non-Hodgkin lymphoma market?